The potent IgG4-inducing antigen in banana is a mannose-binding lectin, BanLec-I.

Int Arch Allergy Immunol

Central Laboratory, The Netherlands' Red Cross Blood Transfusion Service, Amsterdam.

Published: June 1992

IgG4 antibodies to banana were found to occur far more frequently than expected. The most important antigen involved proved to be a lectin, BanLec-I. Because of the lectin nature of the antigen, it was important to establish the antibody nature of the lectin-IgG4 interaction and to exclude an interaction between the sugar-binding site of the lectin and glycosidic chains on IgG4. Three arguments in support of immune binding are: (1) the binding of BanLec-I to IgG4 is mannoside resistant, whereas the binding to all other glycoproteins tested is mannoside inhibitable; (2) only a minor fraction of the IgG4 in serum and none of five IgG4 myelomas tested was bound, and (3) the lectin binds to the Fab fragment of the IgG4 molecule. A curious finding was that in the presence of high-molecular-weight glycoproteins the interaction between IgG4 and BanLec-I was enhanced by alpha-methyl mannoside. The probable explanation of this phenomenon is that complexes of the lectin with high-molecular-weight glycoproteins by sterical interference inhibit the interaction with human IgG4 antibodies (or with rabbit antibodies to the lectin). This inhibition is prevented in the presence of alpha-methyl mannoside. These results support the earlier suggestion that some lectins are particularly prone to induce an immune response upon oral feeding. This banana lectin might be a potentially useful carrier protein for oral antihapten immunization in humans.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000236090DOI Listing

Publication Analysis

Top Keywords

lectin
8
lectin banlec-i
8
igg4
8
banlec-i igg4
8
igg4 antibodies
8
high-molecular-weight glycoproteins
8
alpha-methyl mannoside
8
potent igg4-inducing
4
igg4-inducing antigen
4
antigen banana
4

Similar Publications

MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.

Sci Rep

January 2025

Department of Life Technologies, Division of Biotechnology, University of Turku, Medisiina D, 5th floor, Kiinamyllynkatu 10, 20520, Turku, Finland.

Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles.

View Article and Find Full Text PDF

Dectin-1 (CLEC7A), a C-type lectin-like receptor that recognizes β-1,3 glucans, has a key role in the innate immune system. While the lectin domain of mouse Dectin-1 has been solubilized and refolded from inclusion bodies in Escherichia coli, similar refolding of the human Dectin-1 lectin domain is hindered by the formation of misfolded multimers with aberrant intermolecular disulfide bonds. The aim of this study was to develop a method for the large-scale production of the human Dectin-1 lectin domain.

View Article and Find Full Text PDF

Challenges for complement functional assays in the clinical laboratory: From test validation to clinical interpretation.

J Immunol Methods

January 2025

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America. Electronic address:

Complement functional assays are essential first-tier tests for a gamut of disorders spanning from inborn errors of the immune system which lead to recurrent severe infections, to angioedema attacks, presentation of autoimmune disease, thrombotic microangiopathies and rare kidney disorders. These assays evaluate the activity of the three complement pathways and specific complement components, which helps in differential diagnosis and monitoring disease progression. The rising use of complement inhibitors for treating complement-mediated thrombotic microangiopathies has heightened the demand for personalized treatment plans and laboratory assessment of complement blockage.

View Article and Find Full Text PDF

Ischemic stroke leads to permanent damage to the affected brain tissue, with strict time constraints for effective treatment. Predictive biomarkers demonstrate great potential in the clinical diagnosis of ischemic stroke, significantly enhancing the accuracy of early identification, thereby enabling clinicians to intervene promptly and reduce patient disability and mortality rates. Furthermore, the application of predictive biomarkers facilitates the development of personalized treatment plans tailored to the specific conditions of individual patients, optimizing treatment outcomes and improving prognoses.

View Article and Find Full Text PDF

Endocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors.

Inflamm Res

January 2025

Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 3, 4200-450, Porto, Portugal.

Background And Aims: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment.

Material And Methods: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!